BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20617532)

  • 1. Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies.
    Guzian MC; Carrier N; Cossette P; de Brum-Fernandes AJ; Liang P; Ménard HA; Boire G
    Arthritis Care Res (Hoboken); 2010 Nov; 62(11):1624-32. PubMed ID: 20617532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.
    Boire G; Cossette P; de Brum-Fernandes AJ; Liang P; Niyonsenga T; Zhou ZJ; Carrier N; Daniel C; Ménard HA
    Arthritis Res Ther; 2005; 7(3):R592-603. PubMed ID: 15899046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis.
    Jansen LM; van Schaardenburg D; van der Horst-Bruinsma I; van der Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2003 Aug; 30(8):1691-5. PubMed ID: 12913923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis.
    Nielen MM; van der Horst AR; van Schaardenburg D; van der Horst-Bruinsma IE; van de Stadt RJ; Aarden L; Dijkmans BA; Hamann D
    Ann Rheum Dis; 2005 Aug; 64(8):1199-204. PubMed ID: 15640269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.
    Rantapää-Dahlqvist S; de Jong BA; Berglin E; Hallmans G; Wadell G; Stenlund H; Sundin U; van Venrooij WJ
    Arthritis Rheum; 2003 Oct; 48(10):2741-9. PubMed ID: 14558078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis.
    Kroot EJ; de Jong BA; van Leeuwen MA; Swinkels H; van den Hoogen FH; van't Hof M; van de Putte LB; van Rijswijk MH; van Venrooij WJ; van Riel PL
    Arthritis Rheum; 2000 Aug; 43(8):1831-5. PubMed ID: 10943873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
    Greiner A; Plischke H; Kellner H; Gruber R
    Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies in early rheumatoid arthritis: Brasília cohort: results of a three-year serial analysis.
    da Mota LM; Santos Neto LL; Pereira IA; Burlingame R; Ménard HA; Laurindo IM
    Rev Bras Reumatol; 2011 Dec; 51(6):564-71. PubMed ID: 22124591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
    Us D; Gülmez D; Hasçelik G
    Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis.
    Low JM; Chauhan AK; Kietz DA; Daud U; Pepmueller PH; Moore TL
    J Rheumatol; 2004 Sep; 31(9):1829-33. PubMed ID: 15338508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
    Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
    Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
    Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
    Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
    Carrier N; Cossette P; Daniel C; de Brum-Fernandes A; Liang P; Ménard HA; Boire G
    Arthritis Rheum; 2009 Mar; 60(3):698-707. PubMed ID: 19248090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles.
    Irigoyen P; Lee AT; Wener MH; Li W; Kern M; Batliwalla F; Lum RF; Massarotti E; Weisman M; Bombardier C; Remmers EF; Kastner DL; Seldin MF; Criswell LA; Gregersen PK
    Arthritis Rheum; 2005 Dec; 52(12):3813-8. PubMed ID: 16320316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive values of anti-cyclic citrullinated peptide antibody, antikeratin antibody and rheumatoid factor in diagnosing articular erosions in patients with rheumatoid arthritis].
    Xie QB; Yin G
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):508-12. PubMed ID: 19627016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis.
    Xue Y; Zhang J; Chen YM; Guan M; Zheng SG; Zou HJ
    Scand J Rheumatol; 2008; 37(3):183-7. PubMed ID: 18465452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.